| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 66, 605-610, Copyright © 1988 by Endocrine Society
ARTICLES |
JA Sundsfjord, G Thibault, P Larochelle and M Cantin
Clinical Research Institute of Montreal, Quebec, Canada.
A specific RIA was developed to measure plasma atrial natriuretic factor (ANF) N-terminal immunoreactivity in man. Antibodies raised in rabbits against a rat ANF N-terminal fragment [ANF-(11-37)] had 100% cross-reactivity with human ANF-(1-30) and purified plasma N-terminal ANF immunoreactivity. The ED80 and ED50 of standard curves prepared using [125I]human ANF-(1-30) and human ANF-(1-30) were 31.5 +/- 5.4 (+/- SD) and 132.5 +/- 20.4 fmol/tube, respectively. The plasma ANF N- terminal peptide concentrations were assayed directly, without extraction, since dilution of plasma and addition of standard to plasma yielded parallel dose-responses in the RIA and virtually 100% recovery of ANF-(1-30) added to plasma. Purification of ANF N-terminal immunoreactivity from 1.5 L human plasma by affinity chromatography and amino acid sequencing suggested that it was closely related to ANF-(1- 98), although some degraded peptides were also detected. The mean basal plasma ANF N-terminal peptide level measured in 34 normal subjects was 420 +/- 157 (+/- SD) pmol/L. The values were higher in plasma from patients with congestive heart failure (grades III and IV; 7,041 +/- 6,136 pmol/L; n = 13) or chronic renal failure (10,079 +/- 4,942 pmol/L; n = 20). In 9 patients with chronic renal failure, hemodialysis resulted in a 30% (P less than 0.05) decrease in plasma ANF-(99-126) levels, from 34.7 +/- 12.3 (+/- SD) to 23.2 + 6.1 pmol/L, but no changes in plasma ANF N-terminal peptide concentrations. These data indicate that the N-terminal portion of pro-ANF is cosecreted with ANF- (99-126). Its higher plasma levels in the basal state and during chronic renal failure suggest a different process of elimination than that of ANF-(99-126), which may be partly mediated by the kidney.
This article has been cited by other articles:
![]() |
M. Brueckmann, G. Huhle, S. Lang, K. K. Haase, T. Bertsch, C. Weiss, J. J. Kaden, C. Putensen, M. Borggrefe, and U. Hoffmann Prognostic Value of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients With Severe Sepsis Circulation, July 26, 2005; 112(4): 527 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Sabatine, D. A. Morrow, J. A. de Lemos, T. Omland, M. Y. Desai, M. Tanasijevic, C. Hall, C. H. McCabe, and E. Braunwald Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1988 - 1995. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Heringlake, C. Heide, L. Bahlmann, W. Eichler, H. Pagel, P. Schmucker, R. Wergeland, F. P. Armbruster, and S. Klaus Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers J Appl Physiol, July 1, 2004; 97(1): 173 - 179. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. McKelvie, J.-L. Rouleau, M. White, R. Afzal, J. B. Young, A. P. Maggioni, P. Held, and S. Yusuf Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure Eur. Heart J., October 1, 2003; 24(19): 1727 - 1734. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A Sagnella Practical implications of current natriuretic peptide research Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 304 - 315. [PDF] |
||||
![]() |
C. J. Pemberton, M. L. Johnson, T. G. Yandle, and E. A. Espiner Deconvolution Analysis of Cardiac Natriuretic Peptides During Acute Volume Overload Hypertension, September 1, 2000; 36(3): 355 - 359. [Abstract] [Full Text] [PDF] |
||||
![]() |
N Suskin, R.S McKelvie, R.J Burns, R Latini, D Pericak, J Probstfield, J.L Rouleau, C Sigouin, C.B Solymoss, R Tsuyuki, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure Eur. Heart J., August 2, 2000; 21(16): 1368 - 1375. [Abstract] [PDF] |
||||
![]() |
Effects of Metoprolol CR in Patients With Ischemic and Dilated Cardiomyopathy : The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study Circulation, February 1, 2000; 101(4): 378 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Pemberton, T. G. Yandle, M. T. Rademaker, C. J. Charles, G. D. Aitken, and E. A. Espiner Amino-terminal proBNP in ovine plasma: evidence for enhanced secretion in response to cardiac overload Am J Physiol Heart Circ Physiol, October 1, 1998; 275(4): H1200 - H1208. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Numata, K. Dohi, A. Furukawa, S. Kikuoka, H. Asada, T. Fukunaga, Y. Taniguchi, K. Sasakura, T. Tsuji, K. Inouye, et al. Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptidein human plasma Clin. Chem., May 1, 1998; 44(5): 1008 - 1013. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Hopkins and C. Hall Paradoxical Relationship Between N-Terminal Proatrial Natriuretic Peptide and Filling Pressure in Adults With Cyanotic Congenital Heart Disease Circulation, October 7, 1997; 96(7): 2215 - 2220. [Abstract] [Full Text] |
||||
![]() |
H. Leskinen, O. Vuolteenaho, M. Toth, and H. Ruskoaho Atrial Natriuretic Peptide (ANP) Inhibits Its Own Secretion via ANPA Receptors: Altered Effect in Experimental Hypertension Endocrinology, May 1, 1997; 138(5): 1893 - 1902. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Leskinen, O. Vuolteenaho, and H. Ruskoaho Combined Inhibition of Endothelin and Angiotensin II Receptors Blocks Volume Load–Induced Cardiac Hormone Release Circ. Res., January 1, 1997; 80(1): 114 - 123. [Abstract] [Full Text] |
||||
![]() |
K. Yamamoto, J. C. Burnett Jr, M. Jougasaki, R. A. Nishimura, K. R. Bailey, Y. Saito, K. Nakao, and M. M. Redfield Superiority of Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Systolic and Diastolic Dysfunction and Ventricular Hypertrophy Hypertension, December 1, 1996; 28(6): 988 - 994. [Abstract] [Full Text] |
||||
![]() |
T. Omland, A. Aakvaag, V. V. S. Bonarjee, K. Caidahl, R. T. Lie, D. W. T. Nilsen, J. A. Sundsfjord, and K. Dickstein Plasma Brain Natriuretic Peptide as an Indicator of Left Ventricular Systolic Function and Long-term Survival After Acute Myocardial Infarction : Comparison With Plasma Atrial Natriuretic Peptide and N-Terminal Proatrial Natriuretic Peptide Circulation, June 1, 1996; 93(11): 1963 - 1969. [Abstract] [Full Text] |
||||
![]() |
H. Vierimaa, M. Hirvinen, V. Tervonen, O. Arjamaa, H. Ruskoaho, and O. Vuolteenaho Pronatriuretic peptide is a sensitive marker of the endocrine function of teleost heart Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E843 - E850. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |